Baloxavir marboxil in japanese pediatric patients with influenza: Safety and clinical and virologic outcomes

Clinical Infectious Diseases

Volumn 71, Issue 4, 2020, Pages 971-981

  Hirotsu, Nobuo ^a   Sakaguchi, Hiroki ^b   Sato, Chisako ^b   Ishibashi, Toru ^b   Baba, Keiko ^b   Omoto, Shinya ^b   Shishido, Takao ^b   Tsuchiya, Kenji ^b   Hayden, Frederick G ^c   Uehara, Takeki ^b   Watanabe, Akira ^d  

^a Hirotsu Clinic   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c UNIVERSITY OF VIRGINIA   (United States)

^d TOHOKU BUNKA GAKUEN UNIVERSITY   (Japan)

Author keywords

Antiviral; Baloxavir marboxil; Children; Influenza; Japan

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BALOXAVIR MARBOXIL; ANTIVIRUS AGENT; BALOXAVIR; DIBENZOTHIEPIN DERIVATIVE; MORPHOLINE DERIVATIVE; PYRIDONE DERIVATIVE; TRIAZINE DERIVATIVE;

ALLERGIC RHINITIS; AMINO ACID SUBSTITUTION; ANTIBODY TITER; ARTICLE; BACKACHE; BACTERIAL INFECTION; BRONCHITIS; CHICKENPOX; CHILD; CLINICAL OUTCOME; CONSTIPATION; DEHYDRATION; DENTAL CARIES; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HEMATURIA; HERPETIC STOMATITIS; HUMAN; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA B; JAPANESE (PEOPLE); LIGAMENT INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NIGHTMARE; NONHUMAN; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SPRAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRUS DETECTION; VIRUS SHEDDING; VOMITING; INFANT; JAPAN;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DIBENZOTHIEPINS; HUMANS; INFANT; INFLUENZA, HUMAN; JAPAN; MORPHOLINES; PYRIDONES; TRIAZINES;

EID: 85089617383     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciz908     Document Type: Article

References (34)

1. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis 2019; 68:e1-e47.
2. World Health Organization. Weekly Epidemiological Record (WER) 23. November 2012; 87: 461-476. Available at: https://www.who.int/wer/2012/wer8747/en/. Accessed 5 April 2019.
3. Wong KK, Jain S, Blanton L, et al. Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics 2013; 132:796-804.
4. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis. Lancet 2011; 378:1917-30.
5. Reed C, Katz JM, Hancock K, Balish A, Fry AM; H1N1 Serosurvey Working Group. Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic. PLoS One 2012; 7:e48187.
6. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-702.
7. Jackson ML, Chung JR, Jackson LA, et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med 2017; 377:534-43.
8. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202.
9. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47:339-45.
10. Sato M, Saito R, Sato I, et al. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. Tohoku J Exp Med 2008; 214:113-20.
11. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98:174-85.
12. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54:2575-82.
13. Hurt AC, Hardie K, Wilson NJ, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148-57.
14. Takashita E, Ejima M, Itoh R, et al. A community cluster of influenza A(H1N1) pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill 2014; 19:20666.
15. Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res 2018; 160:109-17.
16. Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 2018; 8:9633.
17. Hayden FG, Sugaya N, Hirotsu N, et al; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379:913-23.
18. Uehara T, Hayden FG, Kawaguchi K, et al. Treatment emergent influenza variant viruses with reduced baloxavir susceptibility: Impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 2019. jiz244.
19. Koshimichi H, Ishibashi T, Wajima T. Population pharmacokinetics of baloxavir marboxil in Japanese pediatric influenza patients. J Pharm Sci 2019; 108:3112-7.
20. Koshimichi H, Tsuda Y, Ishibashi T, Wajima T. Population pharmacokinetic and exposure-response analyses of baloxavir marboxil in adults and adolescents including patients with influenza. J Pharm Sci 2019; 108:1896-904.
21. Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: Phase I study findings. Clin Drug Investig 2018; 38:1189-96.
22. Noshi T, Satou K, Ishibashi T, et al. Pharmacokinetic and pharmacodynamic analysis of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, in mice infected with influenza A virus [P1973]. In: Final Programme of the 27th European Congress of Clinical Microbiology and Infectious Diseases (Vienna). Basel: European Society of Clinical Microbiology and Infectious Diseases, 2017.
23. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33.
24. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: A randomized controlled trial. Clin Infect Dis 2010; 51:887-94.
25. Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: A randomised placebo-controlled trial. Lancet Infect Dis 2014; 14:109-18.
26. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012; 56:369-77.
27. Suzuki E, Ichihara K. The course of fever following influenza virus infection in children treated with oseltamivir. J Med Virol 2008; 80:1065-71.
28. Koseki N, Kaiho M, Kikuta H, et al. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Influenza Other Respir Viruses 2014; 8:151-8.
29. Ishiguro N, Koseki N, Kaiho M, et al. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan. J Infect Chemother 2018; 24:449-57.
30. Takashita E, Kawakami C, Morita H, et al. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill 2019; 24:1800698.
31. Pharmaceuticals and Medical Devices Agency. 2018. Review report on Xofluza. 17 January 2018. Available at: https://www.pmda.go.jp/files/000225380.pdf. Accessed 5 April 2019.
32. Takashita E, Kawakami C, Ogawa R, et al. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill 2019; 24:1900170.
33. National Institute Infectious Disease. Infectious Agents Surveillance Report (IASR) 12 March 2019. Available at: https://www.niid.go.jp/niid/ja/flu-m/fluiasrs/8664-470p01.html. Accessed 5 April 2019.
34. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2017 -2018. Pediatrics 2017; 140:e20173535.